| Bioactivity | NU9056 is a potent and selective Tip60 (KAT5) histone acetyltransferase inhibitor with an [1][2] of 2 µM. NU9056 shows >16-fold selectivity for Tip60 over PCAF, p300 and GCN5. NU9056 induces apoptosis of prostate cancer cells[1]. | ||||||||||||
| Invitro | NU9056 (17-36 µM; 24-96 hours) results in both caspase 3 and caspase 9 activation in a time- and concentration-dependent manner[1]. NU9056 (2.5-40 µM; 2 hours) treatment results in decreased levels of acetylated histone H4K16, H3K14 and H4K8, targets for Tip60-mediated acetylation[1].NU9056 treatment also decreases androgen receptor, prostate specific antigen, p53 and p21 protein levels[1]. Apoptosis Analysis[1] Cell Line: | ||||||||||||
| Name | NU9056 | ||||||||||||
| CAS | 1450644-28-6 | ||||||||||||
| Formula | C6H4N2S4 | ||||||||||||
| Molar Mass | 232.37 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|